Back to Journals » Cancer Management and Research » Volume 17

EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway [Retraction]

Authors Zhang R, Han D, Li L, Luo W, Liu J, Qian L

Received 3 July 2025

Accepted for publication 3 July 2025

Published 5 July 2025 Volume 2025:17 Pages 1313—1314

DOI https://doi.org/10.2147/CMAR.S551287



Zhang R, Han D, Li L, Luo W, Liu J, Qian L. Cancer Manag Res. 2020;12:9539—9549.

We, the Editors and Publisher of the journal Cancer Management and Research have retracted the published article.

After publication, concerns have been raised by a third party about the integrity of the data in Figure 2 of the article.

Further investigations conducted by the Journal and Publisher identified multiple article integrity concerns, including duplicate image panels representative of different treatment conditions present in Figure 2 of the article. The authors have not responded to the queries raised by the Journal and Publisher.

As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’. 


This retraction relates to this paper


Creative Commons License © 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.